Abstract:Epilepsy is a complex and multifaceted neurological disorder characterized by spontaneous and recurring seizures. It poses significant therapeutic challenges due to its diverse etiology and often-refractory nature. This comprehensive review highlights the pivotal role of AMP-activated protein kinase (AMPK), a key metabolic regulator involved in cellular energy homeostasis, which may be a promising therapeutic target for epilepsy. Current therapeutic strategies such as antiseizure medication (ASMs) can alleviate seizures (up to 70%). However, 30% of epileptic patients may develop refractory epilepsy. Due to the complicated nature of refractory epilepsy, other treatment options such as ketogenic dieting, adjunctive therapy, and in limited cases, surgical interventions are employed. These therapy options are only suitable for a select group of patients and have limitations of their own. Current treatment options for epilepsy need to be improved. Emerging evidence underscores a potential association between impaired AMPK functionality in the brain and the onset of epilepsy, prompting an in-depth examination of AMPK’s influence on neural excitability and ion channel regulation, both critical factors implicated in epileptic seizures. AMPK activation through agents such as metformin has shown promising antiepileptic effects in various preclinical and clinical settings. These effects are primarily mediated through the inhibition of the mTOR signaling pathway, activation of the AMPK-PI3K-c-Jun pathway, and stimulation of the PGC-1α pathway. Despite the potential of AMPK-targeted therapies, several aspects warrant further exploration, including the detailed mechanisms of AMPK’s role in different brain regions, the impact of AMPK under various conditional circumstances such as neural injury and zinc toxicity, the long-term safety and efficacy of chronic metformin use in epilepsy treatment, and the potential benefits of combination therapy involving AMPK activators. Moreover, the efficacy of AMPK activators in refractory epilepsy remains an open question. This review sets the stage for further research with the aim of enhancing our understanding of the role of AMPK in epilepsy, potentially leading to the development of more effective, AMPK-targeted therapeutic strategies for this challenging and debilitating disorder.

Adrenergic receptor system as a pharmacological target in the treatment of epilepsy (Review)

Insight into Drug Resistance in Status Epilepticus: Evidence from Animal Models

Adenosine receptors in brain: Neuromodulation and role in epilepsy

Putative Role of Adenosine A1 Receptors in Exogenous Ketone Supplements-Evoked Anti-Epileptic Effect

The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy

The Potential Therapeutic Capacity of Inhibiting the Brain Renin–Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy

Revisiting the role of neurotransmitters in epilepsy: An updated review

Anti-seizure Medications: Challenges and Opportunities

Nicotinic acetylcholine receptors and epilepsy

Therapeutic potential of ketamine in management of epilepsy: Clinical implications and mechanistic insights

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

New anti-epileptic drugs

Neural stimulation systems for the control of refractory epilepsy: a review

Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs

AMPK role in epilepsy: a promising therapeutic target?

Emerging drugs for focal epilepsy

Is elevated norepinephrine an etiological factor in some cases of epilepsy?

Established and emerging GABAA receptor pharmacotherapy for epilepsy

Feedback Control of Neuronal Excitability and Epileptiform Bursting using a Photocaged Adenosine A1 Agonist

The ATP-Gated P2X7 Receptor As a Target for the Treatment of Drug-Resistant Epilepsy

Medical management of epileptic seizures: challenges and solutions